Table 1 Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer patients who received multigene assays.

	Pathologic complete response		Logistic regression
Variable	Not achieved	Achieved	OR (95% CI)	P value	AOR (95% CI)	P value
	No. (row %)	No. (row %)
Oncotype DX recurrence score^a
Continuous, Mean (SD)	27.9 (13.7)	42.5 (15.5)	1.80 (1.61–2.00)^b	<0.0001	1.58 (1.38–1.80)^b,c	<0.0001
Categorical^d
0–25	853 (98.4)	14 (1.6)	1.0 (reference)		1.0 (reference)
26–100	1049 (88.8)	132 (11.2)	7.67 (4.39–13.4)	<0.0001	4.48 (2.44–8.22)^c	<0.0001
MammaPrint result
Any early-stage breast cancer
Low risk	>198 (>95.2)	<10 (<4.8)^g	1.0 (reference)		1.0 (reference)
High risk	947 (83.0)	194 (17.0)	4.53 (2.28–8.99)	<0.0001	2.21 (1.02–4.77)^e	0.04
Hormone receptor-positive
Low risk	>190 (>95.0)	<10 (<5.0)	1.0 (reference)		1.0 (reference)
High risk	778 (88.2)	104 (11.8)	3.21 (1.54–6.70)	0.002	2.25 (0.99–5.15)^f	0.05

SD standard deviation, OR odds ratio, CI confidence interval, AOR adjusted odds ratio, PR progesterone receptor, ER estrogen receptor, HER2 human epidermal growth factor receptor 2.
^aThe Oncotype DX cohort included patients with hormone receptor (HR)-positive/HER2-negative stage I–III disease.
^bOdds ratio per 10 unit increase in Oncotype DX score.
^cAdjusted for age, race/ethnicity, PR status, clinical T and N stages, and tumor grade.
^dOncotype DX recurrence score was dichotomized per the TAILORx trial cutoff.
^eAdjusted for age, race/ethnicity, PR status, ER status, HER2 status, clinical T and N stages, and tumor grade.
^fAdjusted for age, race/ethnicity, PR status, HER2 status, clinical T and N stages, and tumor grade.
^gAs per NCDB requirement to protect the confidentiality of patients, we suppressed reporting of frequencies <10.

Quick links

Search